Skip to content

Measuring how strongly the nipple and areola glow (fluorescence) and how sugar measurments in the tissue can help to predict how well blood circulates in the nipple-areola complex during a nipple-sparing breastamputation.

Fluorescence Intensity & Nipple Glucose Measurements as Predictors of Tissue Perfusion of the Nipple-Areola Complex in Nipple-Sparing Mastectomy - Fluorescence Intensity & Nipple Glucose Measurements as Predictors of Tissue Perfusion of the Nipple-Areola Complex in Nipple-Sparing Mastectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON58453
Enrollment
15
Registered
2025-09-03
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partial or double mastectomy with concomitant or subsequent breast reconstruction Concerning a type of surgical operation in which one or both breasts are completely of partly removed and in which the breast is reconstructed during the same operation

Interventions

Intra operative use of indocyaninegroen angiografie (ICG) in reconstructive surgery

Sponsors

University of Buenos Aires
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Female adults within the ages of 18 to 75-yearsPatients undergoing the eligible procedures in an elective fashion (see ‘Clincal data’ section for the listed procedures) Patients able to agree and provide verbal and written consent for participation in this study

Exclusion criteria

Exclusion criteria: Patients will be ineligible for entry in this study if any of the following conditions are met Patients outside the eligible age range Patients with a prior history of breast or thoracic surgery, or prior history of radiotherapy Patients actively pregnant or considering pregnancy. Patients with a known or prior history of allergy to iodine

Design outcomes

Primary

MeasureTime frame
Main study endpoints: Fluorescent intensity phases of ICG video recorded (defined in px/s), glucose index score (GIS); being the nipple-areolar complex glucose levels (capillary) corrected with serum glucose levels (venous serum). 

Secondary

MeasureTime frame
Basic demographics, general and specific comobidities , intra operative information about the ICG administration and information about the surgical site, presence of complications

Countries

Argentina, Guatemala, Italy, Netherlands

Contacts

Public ContactKW Roskamp

Zuyderland

k.roskamp@student.maastrichtuniversity.nl088 - 459 97 05

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Mar 20, 2026